Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
Authors:
- Michael TanenMTMichael Tanen
- Amy Q. WangAWAmy Q. Wang
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (1) , 55-72
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- What do we know about the secretion and degradation of incretin hormones?Regulatory Peptides, 2005
- Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Therapeutic Strategies Based on Glucagon-Like Peptide 1Diabetes, 2004
- Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Gut peptides and type 2 diabetes mellitus treatmentCurrent Diabetes Reports, 2003
- Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic RatsDiabetes, 2003
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2003
- Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 DiabetesDiabetes Care, 2002
- Oral Antihyperglycemic Therapy for Type 2 DiabetesJAMA, 2002
- Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of DiabetesCurrent Pharmaceutical Design, 2001